Boston Medical Center

ISMP Announces 26th Annual Cheers Award Recipients

Retrieved on: 
Lundi, novembre 20, 2023
Western Kentucky University, Safety, Research, Organization, Life, RaDonda Vaught homicide case, Trauma, Sibling, FAAN, ADC, Hospital, Patient safety organization, MUHC, Patient, RN, Sinclair School of Nursing, Agency, House, BSN, Joint Commission, Vaccine, PPID, Boston Medical Center, American Hospital Association, University, Infection, Software, Information technology, BCMA, Approximation error, CPPS, Pharmaceutical industry, Nursing

PLYMOUTH MEETING, Pa., Nov. 20, 2023 /PRNewswire/ -- The Institute for Safe Medication Practices (ISMP) is proud to announce the 26th Annual Cheers Awards winners, who have shown outstanding dedication to reducing adverse events and infection exposure, and a Lifetime Award Winner who has focused her career on helping support practitioners involved in accidental errors that harm patients. This year's speaker will be RaDonda Vaught, a former nurse prosecuted for her role in a fatal medication error in one of the highest profile healthcare-related criminal cases in recent years.

Key Points: 
  • ISMP Cheers Awards winners are leaders in safety technology implementation and support for second victims of errors.
  • The ISMP Cheers Awards honor individuals, organizations, and companies that have set a standard of excellence in medication safety; for more information, visit: https://www.ismp.org/cheers-awards .
  • The winners of this year's ISMP Cheers Awards are:
    Boston Medical Center's Medication Safety and Quality Committee is receiving a Cheers Award for its implementation of barcode medication administration (BCMA) and positive patient identification (PPID) in ambulatory care settings.
  • One of the 2023-2024 ISMP Targeted Medication Safety Best Practices for Hospitals calls for expanding BCMA beyond inpatient areas.

TraceLink Secures Merit Award for Healthcare Innovation with AI-Powered Product Availability Intelligence Solution

Retrieved on: 
Jeudi, novembre 16, 2023
Organization, Doctor of Pharmacy, Patient, Boston Medical Center, Intelligence, Health, Supply, MBA, Health care, CSP, PAI, Nursing, Pharmaceutical industry

BOSTON, Nov. 16, 2023 /PRNewswire/ -- TraceLink Inc., the leading digital network platform company enabling end-to-end product orchestration by connecting more than 291,000 healthcare and life sciences entities through its B2N Integrate-Once™ network, is proud to announce that its innovative Product Availability Intelligence (PAI) solution has been recognized with a Bronze award by the prestigious Merit Awards for Healthcare Innovation. Product Availability Intelligence leverages the collective intelligence of the TraceLink network to flag drug shortages up to 90 days in advance so they can be successfully mitigated.

Key Points: 
  • BOSTON, Nov. 16, 2023 /PRNewswire/ -- TraceLink Inc., the leading digital network platform company enabling end-to-end product orchestration by connecting more than 291,000 healthcare and life sciences entities through its B2N Integrate-Once™ network, is proud to announce that its innovative Product Availability Intelligence (PAI) solution has been recognized with a Bronze award by the prestigious Merit Awards for Healthcare Innovation.
  • Product Availability Intelligence leverages the collective intelligence of the TraceLink network to flag drug shortages up to 90 days in advance so they can be successfully mitigated.
  • TraceLink Product Availability Intelligence successfully predicted 70% of these shortages.
  • To learn more about PAI Product Availability Intelligence visit: https://www.tracelink.com/products/intelligence-and-analytics/product-av...
    For the full list of winners visit: https://www.businesswire.com/news/home/20231107462086/en/

IVI RMA To Acquire North American Operations of Eugin Group, Including Boston IVF, Creating a Leading North American Fertility Group

Retrieved on: 
Mercredi, novembre 8, 2023
Research, Nursing, Medical Devices, Hospitals, Health Technology, Other Health, Managed Care, General Health, Health, Science, Fertility, Harvard Medical School, Family, Physician, TRIO, Workplace, Organization, Mazda North American Operations, Acquisition, Growth, IVF, Boston Medical Center, Partnership, Tufts Medical Center, Culture, Reproductive medicine, Fresenius, Patient, RMA, IVI

IVI RMA, one of the largest reproductive medicine groups in the world, has signed a definitive agreement to acquire the North American Operations of Eugin Group, consisting of the Boston IVF fertility network and Toronto-based TRIO, from healthcare group Fresenius.

Key Points: 
  • IVI RMA, one of the largest reproductive medicine groups in the world, has signed a definitive agreement to acquire the North American Operations of Eugin Group, consisting of the Boston IVF fertility network and Toronto-based TRIO, from healthcare group Fresenius.
  • The strategic additions will grow IVI RMA to become a leading fertility group in North America and reinforce the company’s commitment to providing evidence-based fertility solutions with the greatest chance of success to the greatest number of patients.
  • “We are thrilled to welcome Boston IVF, its partner clinics and TRIO to the IVI RMA network as we continue to bring the best fertility science to more markets across North America,” said Javier Sanchez Prieto, CEO of IVI RMA.
  • In addition, we look forward to operational enhancements, including best-in-class electronic medical records technology and a prosperous partnership as we continue to grow in North America as part of IVI RMA.”

Iterative Health Presents Award-Winning Research on the Benefits of Gastroenterological Technology at the American College of Gastroenterology Annual Scientific Meeting

Retrieved on: 
Lundi, octobre 23, 2023
Technology, Surgery, Medical Devices, Medical Supplies, Clinical Trials, Other Health, Health, General Health, Artificial Intelligence, GI, FDA, Intelligence, American College, Harvard Medical School, Crohn's disease, MPH, Outline of health sciences, Adenoma, Use, ACG, Prevalence, Rutgers University–New Brunswick, Cade, Publication, Doctor of Philosophy, MBA, American College of Gastroenterology, Research, Computer science, Computer-aided, George Washington University School of Medicine & Health Sciences, Artificial intelligence, APC, Colonoscopy, School, University of North Dakota, CRC, Clinical trial, Abstract, University, Medical diagnosis, Mount Auburn Hospital, Safety, Boston Medical Center, Inflammatory bowel disease, MS, Medical imaging, Management, Medical device, Gastroenterology, MD, Colitis, Geriatrics, Medicine

Iterative Health , a pioneer in precision-medicine technologies for gastroenterology, announced today the results of new research unveiled at the American College of Gastroenterology (ACG) Annual Scientific Meeting.

Key Points: 
  • Iterative Health , a pioneer in precision-medicine technologies for gastroenterology, announced today the results of new research unveiled at the American College of Gastroenterology (ACG) Annual Scientific Meeting.
  • This research represents strides toward enhancing the detection of precursor adenomas and streamlining clinical trial recruitment processes in gastroenterology, ultimately bringing us closer to a future of advancing patient care in the field.
  • The publications include:
    Authors: William Holderman, MD; Parth Jain; Mitchell Reddan, MS; Haig Soghigian, MBA; Christopher Fourment, MD.
  • To learn more about Iterative Health, please visit iterative.health .

Odyssey Therapeutics Appoints Jeremy Sokolove, MD as Chief Medical Officer

Retrieved on: 
Mercredi, octobre 4, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Odyssey, Abstract, GSK, Bachelor of Science in Human Biology, University, Boston University Chobanian & Avedisian School of Medicine, Emergency medicine, Biochemistry, Internal medicine, Upadacitinib, Lead, Multimedia, Rheumatology, Rheumatoid arthritis, Boston University School of Public Health, Stanford University School of Medicine, Medical research, Vaccine, Division, AbbVie, VA Palo Alto Health Care System, Faculty, Immunology, Pharmacology, Therapy, Boston Medical Center, Giant cell arteritis, Stanford University Medical Center, Inflammation, Pharmaceutical industry, Nursing, Science

Odyssey Therapeutics, Inc. , a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, today announced the appointment of Jeremy Sokolove, M.D., as chief medical officer.

Key Points: 
  • Odyssey Therapeutics, Inc. , a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, today announced the appointment of Jeremy Sokolove, M.D., as chief medical officer.
  • In this role, Dr. Sokolove will develop, lead and drive the development strategy and execution of all Odyssey’s clinical assets.
  • View the full release here: https://www.businesswire.com/news/home/20231004996667/en/
    Jeremy Sokolove, M.D., Chief Medical Officer of Odyssey Therapeutics, Inc. (Photo: Business Wire)
    “As the newest member of our executive leadership team, Dr. Sokolove’s medical expertise and background in the biopharmaceutical industry will be critical to the success of our clinical development programs and achieving our corporate goals,” said Gary D. Glick, Ph.D., founder and CEO of Odyssey Therapeutics.
  • “It’s an exciting time to join Odyssey as the organization transitions to a clinical-stage biotechnology company,” said Dr. Sokolove.

Equality Health's Texas Medical Director to Speak at Digital Health Engagement and Experience Summit in Houston

Retrieved on: 
Mardi, septembre 26, 2023
Boston Medical Center, Health, Health equity, Houston Methodist Hospital, Doctor of Philosophy, Parkland Health & Hospital System, MD, Digital transformation, DC Health Link, Dismus Onyiego, Digital, Tufts Health Plan, Equalize Health, Texas Medical Center, Nursing

PHOENIX, Sept. 26, 2023 /PRNewswire/ -- Equality Health, a leader in value-based care, announced today that Sherri Onyiego, MD, PhD, Texas Medical Director for the company, is speaking on a panel at The Healthcare Innovation Company's (thINc) Digital Health Engagement and Experience Summit for Health Plans and Hospital Systems, a two-day event held Sept. 27-28 at The Royal Sonesta Houston Galleria Hotel.

Key Points: 
  • PHOENIX, Sept. 26, 2023 /PRNewswire/ -- Equality Health, a leader in value-based care, announced today that Sherri Onyiego, MD, PhD, Texas Medical Director for the company, is speaking on a panel at The Healthcare Innovation Company's (thINc) Digital Health Engagement and Experience Summit for Health Plans and Hospital Systems, a two-day event held Sept. 27-28 at The Royal Sonesta Houston Galleria Hotel.
  • The panel, "Making an Impact: How Digital Transformation Can Advance Health Equity Efforts" will be moderated by Heather Nelson, Health Equity Leader, Digital Transformation Cross-Industry with Deloitte Consulting.
  • Onyiego will join other health equity experts from DC Health Benefit Exchange Authority, Boston Medical Center and Houston Methodist Hospital.
  • "Making an Impact: How Digital Transformation Can Advance Health Equity Efforts" will be held on day one of the summit, Wed., Sept. 27, 9:20-10:35 a.m. CT, at The Royal Sonesta Houston Galleria, 2222 W Loop S, Houston.

OnPoint Augmented Reality Spine System Accuracy Exceeds Major Existing Navigation, Robotic and AR System 2X-5X in Peer Reviewed Preclinical Studies

Retrieved on: 
Mercredi, septembre 13, 2023
Florida Atlantic University, CT, Radiation, PE, Environment & Energy Publishing, Weill Cornell Medicine, AE, Data science, Neck pain, Anatomy, 3D, NewYork-Presbyterian Hospital, Spine, Congress of Neurological Surgeons, Tulane University, Congress, The Society of Neurological Surgeons, Assistant professor, Patient, Patient safety, Baptist Health, University of Texas Health Science Center Department of Radiology, Artificial intelligence, Hospital, Vision-guided robot systems, Boston Medical Center, MIS, AR, Satellite navigation device, Surveying, Biostatistics

The first presentation entitled "Augmented Reality Guidance System for Spine Surgery: Comparison of Screw Placement Accuracy using Preoperative CT vs lntraoperative 3D Spin" reported for the novel OnPoint Augmented Reality Spine System "PE (positional error) and AE (angular error) with the novel 4k resolution AR system with stereoscopic targeting using either intraoperative or preoperative CT compare favorably to data published for existing navigation, robotic and AR systems.

Key Points: 
  • The first presentation entitled "Augmented Reality Guidance System for Spine Surgery: Comparison of Screw Placement Accuracy using Preoperative CT vs lntraoperative 3D Spin" reported for the novel OnPoint Augmented Reality Spine System "PE (positional error) and AE (angular error) with the novel 4k resolution AR system with stereoscopic targeting using either intraoperative or preoperative CT compare favorably to data published for existing navigation, robotic and AR systems.
  • The second presentation entitled "Accuracy of an Augmented Reality Spine Surgery Guidance System with Stereoscopic Targeting Head Mounted Display Compared to Standard Computer Navigation, Robotic Systems and Existing AR Systems" reported an improvement in accuracy for the novel OnPoint Augmented Reality Spine System for positional error (PE) and angular error (AE) exceeding that of major existing navigation, robotic and augmented reality systems between 2X - 5X, with the differences being statistically highly significant across all comparisons.
  • The investigators concluded "PE and AE for placing pedicle screws are statistically significantly smaller for the novel AIm-AR system compared to existing navigation, robotic, and AR systems studied.
  • It is not only more accurate, but much lighter than existing AR systems I have used.

AgNovos Bioscience Announces 150th Patient Enrolled in RESTORE Randomized, Controlled Trial

Retrieved on: 
Mardi, août 8, 2023
Science, Biotechnology, Research, Surgery, Health, Medical Devices, Health Technology, Clinical Trials, Geneva University Hospitals, Journal of Orthopaedic Trauma, Osteoporosis, Senior, Internal medicine, Hip, Boston Medical Center, Woman, Bone disease, Trial of the century, Bone, Organization, Andrew Kerr (festival co-founder), Local, Patient, Fracture, Risk, Disease, Mortality, Trauma, Dentistry, Medical device

The Company has activated more than 30 study sites across Japan, Germany, Spain, France, Italy, the UK, the Netherlands and Austria.

Key Points: 
  • The Company has activated more than 30 study sites across Japan, Germany, Spain, France, Italy, the UK, the Netherlands and Austria.
  • RESTORE is expected to include more than 50 study sites and enroll at least 650 patients.
  • “The initiation of RESTORE and the enrollment of the 150th patient is a major milestone for the Company,” explained James Pilachowski, Senior Vice President of Hip Program.
  • I look forward to reviewing the data generated by RESTORE with other clinicians and organizations committed to addressing secondary hip fracture risk.”

CorMedix Inc. Reports Second Quarter and Six Month 2023 Financial Results and Provides Business Update

Retrieved on: 
Mardi, août 8, 2023
Exercise, NTAP, Centers for Medicare & Medicaid Services, Marketing, Infection, Boston Medical Center, Dialysis, Medicare, Net, Incidence, Prescription Drug User Fee Act, Investment, Patient, Patient safety, Risk, PDUFA, Prospective payment system, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Life insurance, Cryptocurrency

CorMedix completed an equity offering in July 2023 which generated net proceeds of approximately $43.2 million.

Key Points: 
  • CorMedix completed an equity offering in July 2023 which generated net proceeds of approximately $43.2 million.
  • Operating expenses in the second quarter of 2023 increased approximately 43% to $11.8 million, compared with $8.3 million in the second quarter of 2022.
  • In addition, CorMedix received approximately $43.2 million in net proceeds from its equity financing that closed in July of 2023.
  • The management team of CorMedix will host a conference call and webcast today, August 8, 2023, at 8:30 AM Eastern Time, to discuss recent corporate developments and financial results.

Avalyn Pharma Expands Executive Team with Appointment of Howard M. Lazarus, MD, FCCP to the Role of Chief Medical Officer

Retrieved on: 
Lundi, août 7, 2023
Lazarus, Bachelor of Science in Human Biology, University of California, San Diego Performance-Based Skills Assessment, Gilead Sciences, Bronchiolitis, Drug development, University, Therapy, Biochemistry, Internal medicine, PAH, Physician, Pulmonary fibrosis, Boehringer Ingelheim, Health, Patient, Annals of the American Thoracic Society, Associate, American College of Chest Physicians, McGill University, FCCP, Nursing care plan, American College, Orthostatic hypertension, IPF, Boston Medical Center, Pharmaceutical industry, Science

Dr. Lazarus brings valuable clinical and drug-development experience to the Avalyn executive team.

Key Points: 
  • Dr. Lazarus brings valuable clinical and drug-development experience to the Avalyn executive team.
  • "Howard’s appointment comes at a critical time in our clinical development," explained Lyn Baranowski , Avalyn’s CEO.
  • In that role, he diagnosed and treated patients with complex pulmonary vascular and interstitial diseases such as IPF and PAH.
  • I’m looking forward to working with the team to advance these product candidates into additional clinical trials and along their path towards approval by the regulatory agencies.”